However, although BCR-ABL1/EGFP+ leukaemia cells were still present in PB of dasatinib-treated Gdpd3+/+ retro-CML-affected mice (Supplementary Fig. 9c), they were dramatically decreased in PB from dasatinib-treated Gdpd3−/− retro-CML-affected mice (Supplementary Fig. 9d). The gene discussed is GDPD3; the disease is leukemia.